F4-Isoprostanes: A Novel Class of Prostanoids Formed during Peroxidation of Docosahexaenoic Acid (DHA)
Biochemical and Biophysical Research Communications 242(2): 338-344
Article 1998 English
Authors
JN
Jaffar Nourooz‐Zadeh
EL
Edwin H. C. Liu
EÄ
Erik Änggård
Abstract
1 min read
Isoprostanes are prostaglandin (PG)-like compounds derived from free radical-catalyzed peroxidation of polyunsaturated fatty acids. F2-isoprostanes are produced in vivo by a non-cyclooxygenase mechanism involving free radical peroxidation of arachidonic acid. Peroxidation of eicosapentaenoic acid produces F3-isoprostanes. In this study, we explore the possibility of formation of F4-isoprostanes during peroxidation of docosahexaenoic acid (DHA) in vitro. DHA-liposomes were exposed at 37°C to either 2, 2′-azobis-(2-amidinopropane) hydrochloride (AAPH) or copper ions at final concentrations of 10 mM and 50 μM, respectively. Sample processing involved solid-phase extraction on a C18and an NH2- cartridge. After conversion to pentafluorobenzyl ester and trimethylsilyl derivatives, F4-isoprostanes were analysed by negative ion-chemical ionisation mass spectrometry using tetradeuterated PGF2α(PGF2-d4) as the internal standard. Quantitative analysis was carried out by selected ion monitoring (SIM) of the carboxylated anion [M-180]−at m/z 593 and 573 for the F4-isoprostanes and PGF2-d4, respectively. DHA oxidised by AAPH or by copper ions gave rise to a similar family of F4-isoprostanes. Formation of F4-isoprostanes increased throughout the oxidation period and was correlated with other indices of lipid peroxidation (hydroperoxides and thiobarbituric acid reactive substances). The possibility of analyzing F4-isoprostanes should provide new opportunities for studying the role of lipid peroxidation in nutritional studies and in the pathogenesis of neurodegenerative diseases.
Okezie I. Aruoma, Monica Deiana, Andrew M. Jenner, Barry Halliwell, Harparkash Kaur, Sebastiano Banni, Francesco P. Corongiu, Ma Dessì, Robert Aeschbach
Discussion(0)
No comments yet. Be the first to comment.